Ascentage Pharma Group International has recently announced the submission of a new drug application for lisaftoclax in China, marking a significant milestone in the program's progress. This novel Bcl-2 inhibitor has demonstrated antitumor activity in both previously untreated patients and those treated with venetoclax, addressing critical treatment gaps in difficult-to-treat myeloid malignancies. If approved, lisaftoclax would be the second Bcl-2 inhibitor to receive approval globally. This regulatory submission underscores Ascentage Pharma's commitment to developing innovative therapies for patients with limited treatment options.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。